Intact Investment Management Inc. Purchases 2,500 Shares of AbbVie Inc. $ABBV

Intact Investment Management Inc. raised its position in AbbVie Inc. (NYSE:ABBV) by 2.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,200 shares of the company’s stock after buying an additional 2,500 shares during the quarter. Intact Investment Management Inc.’s holdings in AbbVie were worth $24,358,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Evolution Wealth Management Inc. bought a new position in AbbVie during the second quarter worth about $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $36,000. Bear Mountain Capital Inc. increased its holdings in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares during the period. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie in the second quarter valued at approximately $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV opened at $219.21 on Monday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market cap of $387.42 billion, a price-to-earnings ratio of 166.07, a PEG ratio of 0.90 and a beta of 0.36. The business’s fifty day moving average is $225.60 and its 200-day moving average is $217.60.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the company earned $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s payout ratio is presently 524.24%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ABBV shares. JPMorgan Chase & Co. increased their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Piper Sandler reiterated an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Guggenheim increased their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a research note on Thursday, January 15th. Finally, Citigroup cut their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $248.11.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.